argenx shared trial and real-world data on Vyvgart (efgartigimod alfa) in patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive at the European Academy of Neurology (EAN) Annual Meeting. In gMG, Vyvgart demonstrated consistent and repeatable improvements across patient subtypes, a… Read More
Researchers from the Institute of Cardiovascular Sciences at the University of Birmingham, UK, have produced the first binding molecules (ligands) of defined composition to make platelets clump together in a predictable way. The research team, led by Professor Steve Watson and Dr Eleyna Martin, developed antibody… Read More
CDR-Life has reached a development milestone with its antibody fragment-based drug candidate that could significantly slow down the progression of geographic atrophy (GA). Boehringer Ingelheim and CDR-Life entered a collaboration and licensing agreement in May 2020 and announced the selection of an antibody fragment-based therapeutic candidate… Read More
Advancements in antibody engineering technologies have greatly enhanced the generation of recombinant antibodies in various formats as therapeutic agents. There are already more than 100 antibody-based drugs approved by the FDA, and numerous antibodies are currently in their late-stage clinical studies. Compared to monoclonal antibodies produced using traditional hybridoma techniques,… Read More
